Kidneys are primarily responsible for drug elimination and are highly vulnerable for toxicity, especially during the use of a combination of nephrotoxic drugs. The present study compared the renal function in cancer patients using different combinational treatment protocols, which are currently used in the patients presented to the clinical settings. To do so, a total of 57 cancer patients already recorded as cancer patients were recruited and their medical files were investigated for demographic characteristics. Patients’ records were used for procuring data regarding their characteristics and treatment profiles. The patients were sub-classified based on the chemotherapeutic medications used into platinum-based regimen (PBR), targeted therapy regimen (TTR), anthracycline-based regimen (ABR), taxane-based regimen (TBR), antimetabolite regimen (AmR), and immunotherapy regimen (ITR). Four millilitres of venous blood was withdrawn from overnight fasting cancer patients, serum separated, and frozen at -20°C. An enzyme-linked immunosorbent assay (ELISA)-based technique was used to determine creatinine and urea from serum. The patients enrolled in the present study were middle-aged adults (56.6±15.2 years), mostly females 48, 84.2%). The common cancer type was breast cancer (36.8%), and the least common type was ovarian cancer (7%). Serum creatinine and urea in patients with uterine cancer (141.7±41.5 and 6.08±1.17 μmol/L, respectively) were significantly (p<0.05) higher than those of breast cancer, lung cancer, and ovarian cancer. The serum creatinine levels in TBR (106.2±42.8) and TTR (106.2±42.8) groups were significantly (p<0.05) higher compared to all other groups. Conversely, the lowest creatinine levels were reported in the AmR group (66.8±18.9). Renal function has shown deterioration in the case of uterine cancer compared to lung, ovarian, and breast cancers. The renal function impairment was significantly associated with targeted therapy regimen and taxane-based regimen. Moreover, the outcomes revealed that renal function in the immunotherapy regimen was better compared to other regimens. These findings necessitate baseline assessment of renal function prior to anticancer therapy and monitoring of renal function. This aspect should be considered in particular in uterine cancer patients.